AASDL 2012: A shift to direction action in hepatitis C?
This article was originally published in Scrip
New antivirals that that allow for interferon-sparing regimens for treating hepatitis C drugs are set to dominate pharmaceutical thinking at this year’s meeting of the American Association for the Study of Liver Diseases in Boston on 9-13 November.
You may also be interested in...
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.